4 results
Approved WMOPending
Our primary aim is to assess the (cost-)effects of the ACCESS system in the support of exacerbation self-management of patients with COPD.
Approved WMOCompleted
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
Approved WMORecruiting
To study the effect of crizanlizumab on the hemodynamics of the cerebral vasculature (CBF and CVR)
Approved WMOCompleted
To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease at 12 months